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Abstract We sought associations among metabolic pro-
files, copeptin levels, emotional control, personality traits,
and hypothalamic–pituitary–adrenal axis activity in meta-
bolically obese normal-weight young women (MONW). We
assessed body composition, including fat-free mass; body fat
(BF) and android and gynoid fat depots; fasting blood glu-
cose, insulin, copeptin, cortisol (baseline and after dexa-
methasone), adrenocorticotropin (ACTH), triglycerides,
total cholesterol, low- (LDL) and high-density (HDL) lipo-
proteins; and the BCL1 and N363S polymorphisms of the
glucocorticoid receptor gene in 59 MONW and 71 healthy
women aged 20–40 years. We also evaluated personality
traits using the NEO-Five Factor Inventory and the sub-
jective extent of emotional suppression by the Courtauld
Emotional Control Scale. Compared to the controls, MONW
had significantly higher insulin, cholesterol, LDL, triglyc-
erides, and waist circumference, but lower HDL. MONW
also had increased BF ([30 % of weight) and unfavorable
regional fat distribution with excess android fat. The android/
BF ratio was 8.29 % (MONW) versus 7.89 % (controls)
(p = 0.005), while the gynoid/BF ratio was 31.99 versus
34.1 %, respectively (p = 0.008). Despite similar ACTH
levels in both groups, MONW had higher cortisol levels both
at the baseline (p \ 0.001) and in the dexamethasone sup-
pression test (p = 0.003). Copeptin levels and the distribu-
tion of glucocorticoid receptor polymorphisms were similar
in both groups. There were also no significant differences in
psychological features between MONW and controls. In
conclusion, the MONW phenotype was associated with
hypothalamic–pituitary–adrenal axis dysregulation, unfa-
vorable metabolic profiles, and fat accumulation, but normal
distribution of glucocorticoid receptor gene polymorphisms
and copeptin levels, and no significant differences in psy-
chological features between MONW and controls.
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Introduction
The metabolically obese, normal-weight (MONW) pheno-
type is associated with a high risk of insulin resistance,
impaired glucose tolerance, dyslipidemia, hypertension, and
excess body fat [1–3]. It has been suggested that the largest
MONW group comprises middle-aged subjects in whom
early intervention based on physical activity and dietary
restrictions might be greatly beneficial [1, 3, 4]. However, in
the general population, the MONW phenotype is commonly
underdiagnosed, mainly due to youth, normal body mass
index (BMI) and, typically, normal medical history [5, 6].
Moreover, early identification of MONW subjects is impe-
ded by the lack of uniform diagnostic criteria. Earlier studies
sought to simplify the complex criteria originally proposed
by Ruderman et al. [7] and were based on a single mea-
surement of insulin resistance via the hyperinsulinemic-
euglycemic clamp protocol [8], fasting insulin level [9], or
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surrogate indices of insulin resistance such as homeostasis
model assessment (HOMA-IR) [3]. In addition to normal or
slightly elevated BMI, other studies proposed visceral fat
[100 cm3 in computed tomography [2], and the coexistence
of impaired glucose tolerance [10] or metabolic syndrome
[11] as diagnostic criteria for MONW. However, regardless
of the criteria used for diagnosis, a majority of studies found
that MONW subjects frequently display a cluster of typical
obesity-related cardiometabolic abnormalities [1–3, 12, 13].
Some studies performed on healthy, normal-weight sub-
jects suggested possible associations between serum cortisol
concentrations and risk for metabolic disorders [14, 15].
Hypothalamic–pituitary–adrenal axis activity is altered under
stress and may be influenced by changes in individual ability
to suppress certain negative emotions and personality traits
[16, 17]. One of the recently identified stress markers that
might also be associated with metabolic disorders is copeptin
[18–20]. Copeptin is derived from the same precursor mole-
cule, pre-provasopressin, as vasopressin (AVP) and neuro-
physin 2. AVP exerts a potentiating effect on corticotropin-
releasing hormone (CRH), while both agents stimulate adre-
nocorticotropin (ACTH) secretion. There have been no pre-
vious reports evaluating hypothalamic–pituitary–adrenal axis
activity and psychological parameters in MONW individuals.
Therefore, we sought associations among body composition,
anthropometric measurements, copeptin levels, emotional
control, personality traits, and hypothalamic–pituitary–adre-
nal axis activity in young subjects with MONW.
Materials and methods
Study population
The study group comprised 130 healthy, normal-weight,
Caucasian women aged 20–40 years living in the Szczecin
area of Poland. Participants were randomly recruited from
local electoral lists and were invited to participate in the
study with a letter of invitation. The exclusion criteria
were: BMI [25.0 kg/m2; familial hyperlipidemia; history
of thyroid, cardiovascular, kidney, or liver disease; arterial
hypertension; pregnancy; irregular menstruation; and any
medical condition that required pharmacological treatment,
including oral contraceptives taken more recently than
3 months prior to entering the study.
All the participants were interviewed to obtain past
medical history. Physical examinations were performed,
including measurements of blood pressure, heart rate,
weight, height, and waist (WC) and hip (HC) circumference.
The body adiposity index (BAI) was calculated from the
following equation: BAI = HC (cm)/height (m)1.5—18.
Women were classified as MONW when waist circum-
ference was [80 cm and at least two of the following
criteria were met: (1) low-density cholesterol[3.0 mmol/l;
(2) high-density cholesterol\1.29 mmol/l; (3) triglycerides
[1.7 mmol/l; (4) glucose [5.6 mmol/l (the diagnostic
criteria for metabolic syndrome); (5) total cholesterol
[4.9 mmol/l; and (6) HOMA-IR [1.69 [3].
The Pomeranian Medical University Ethics Committee
approved the study protocol and all the subjects gave their
written informed consent.
Assessment of body composition
Body composition, including fat-free mass, body fat (BF),
and android and gynoid fat depots, was assessed by dual-
energy X-ray absorptiometry (DXA) (GE Lunar Prodigy
Advance; Madison, WI, USA; software enCORE version
8.1) according to the standard protocol provided by the
manufacturer. Android fat depots were assessed between the
lines from the top edge of the L2 vertebra to the bottom edge
of the L4 vertebra. Gynoid fat depots were assessed between
the lines running through the greater trochanter of the femur
and the flexion gap in the knee joint.
Biochemical analyses
Biochemical assessments included fasting blood glucose,
insulin, copeptin, cortisol, ACTH, triglycerides, total cho-
lesterol, and low- (LDL) and high-density (HDL) lipopro-
teins. All measurements were performed using commercially
available assays. From fasting glucose and insulin levels, a
HOMA-IR index was calculated using the following equa-
tion: HOMA-IR = insulin (lIU/ml) 9 glucose (mg/dl)/405.
Participants who additionally agreed to undergo the dexa-
methasone suppression test were asked to take 1 mg of
dexamethasone at bedtime and underwent a blood test on the
following day between 7:00 and 8:00 a.m.
Polymorphisms of the glucocorticoid receptor gene
All participants were genotyped for the BCL1 and N363S
polymorphisms of the glucocorticoid receptor gene. DNA
was extracted from the peripheral blood leukocytes (Master
PureTM Complete DNA Purification Kit, Illumina Inc.,
Madison, WI, USA) and both polymorphisms were deter-
mined by PCR–RFLP (polymerase chain reaction—restric-
tion fragment length polymorphism) analysis according to a
protocol described elsewhere [21–23].
Psychological assessment
We applied two psychological assessment tools: the NEO-
Five Factor Inventory (NEO-FFI) and the Courtauld Emo-
tional Control Scale (CECS). The NEO-FFI is a short version
of the NEO PI-R (Revised NEO Personality Inventory), a
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questionnaire that consists of 240 items measuring five per-
sonality traits: extraversion, agreeableness, neuroticism,
openness to experience, and conscientiousness. The NEO-FFI
consists of 60 items (12 items per domain), of which the
participant rates statements on a five-point scale ranging from
‘‘strongly disagree’’ to ‘‘strongly agree.’’
The CECS questionnaire comprised three subscales
(anger, anxiety, and depression) with five statements for
each type of emotion rated by the participant on a five-
point scale. It measures the subjective extent of emotional
suppression in difficult situations. The overall outcome is
given as the total emotion control index [24].
Statistical analysis
Differences between groups were evaluated by the Mann–
Whitney U test for continuous variables and by the Chi square
test with Yates correction or Fisher’s exact test for dichoto-
mous variables. Spearman’s rank correlation coefficients
were calculated to determine the relationships between con-
tinuous variables. Since the majority of variables showed a
skewed distribution, they were logarithmized before per-
forming correlation and regression analyses. Data are pre-
sented as medians and interquartile ranges.
Results
Of 130 women, 59 were classified as MONW (on the basis
of criteria used in this study) and the remaining 71 served
as the control group. Baseline comparisons in anthropo-
metric measurements, metabolic profiles, biochemical
assessment, and body composition between MONW and
healthy controls are shown in Table 1. Compared to the
Table 1 Clinical characteristics, metabolic profiles, and body composition in MONW and controls
MONW (n = 59) Controls (n = 71) p value
Median (IQR) Median (IQR)
Age (years) 33.0 (28–37) 32.0 (27–35) 0.216
Height (cm) 167.0 (162–170) 166.0 (161–169) 0.608
Weight (kg) 62.8 (56.4–66.8) 58.8 (53.4–64.8) 0.053
Body mass index (kg/m2) 22.27 (21.2–23.8) 21.43 (19.5–23.5) 0.049
Waist circumference (cm) 77.0 (71–83) 73.0 (69–78) 0.012
Hip circumference (cm) 97.0 (91–99.5) 94.0 (90–99) 0.232
Waist-to-hip ratio 0.8 (0.76–0.83) 0.77 (0.75–0.81) 0.048
Body adiposity index (%) 26.89 (25.2–29.5) 26.82 (24.2–28.3) 0.363
Systolic blood pressure (mm Hg) 118.0 (105–125) 115.0 (110–120) 0.378
Diastolic blood pressure (mm Hg) 75.00 (70–80) 78.00 (70–89) 0.464
Heart rate (beats per minute) 72.00 (68–80) 72.00 (67–80) 0.904
Body fat (% weight) 35.40 (29.1–38.4) 30.80 (25.1–34.1) <0.001
Body fat (kg) 20.72 (16.7–23.6) 16.64 (13.1–21.3) <0.001
Fat-free mass (kg) 37.97 (35.1–40.4) 38.84 (35.8–41.6) 0.223
Android (kg) 1.72 (1.43–2.13) 1.18 (0.95–1,64) <0.001
Gynoid (kg) 6.45 (4.82–6.93) 6.27 (12.9–16.3) 0.090
Total cholesterol (mmol/l) 5.72 (4.97–6.09) 4.38 (4.07–4.58) <0.001
Triglycerides (mmol/l) 0.79 (0.64–1.08) 0.70 (0.53–0.87) 0.006
HDL-C (mmol/l) 1.58 (1.29–1.89) 1.76 (1.48–1.99) 0.026
LDL-C (mmol/l) 3.34 (2.98–3.88) 2.23 (1.97–2.51) <0.001
Glucose (mmol/l) 5.16 (4.72–5.38) 4.92 (4.72–5.16) 0.073
Insulin (lIU/ml) 7.50 (5.36–9.9) 4.70 (3.4–6.4) <0.001
HOMA-IR 1.57 (1.17–2.25) 1.05 (0.76–1.37) <0.001
Cortisol (nmol/l) 433.1 (303.5–535.2) 304.9 (232.0–413.8) <0.001
Cortisol after dexamethasone (nmol/l)a 31.17 (27.59–35.86) 26.76 (23.45–27.59) 0.003
ACTH (pmol/l) 2.18 (1.80–2.79) 2.18 (2.0–3.61) 0.190
Copeptin (pmol/l) 0.84 (0.57–1.04) 0.75 (0.58–1.27) 0.676
Data are medians and interquartile ranges
Bold values are statistically significant (p \ 0.05)
a The dexamethasone suppression test was performed in 21 MONW and 18 controls
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controls, MONW had significantly higher levels of insulin,
glucose, total cholesterol, LDL, triglycerides, and WC, but
lower HDL. MONW also had increased BF ([30 % of
weight) and unfavorable regional fat distribution with
excess android fat that was comparable gynoid fat. The
android/BF ratio was 8.29 % (MONW) versus 7.89 %
(controls) (p = 0.0053), while the gynoid/BF ratio was
31.99 % versus 34.1 %, respectively (p = 0.008).
In MONW, but not in the controls, a negative correlation
was found between android fat and HDL (R = -0.312;
p = 0.016). Moreover, android fat correlated positively
with total cholesterol (R = 0.280; p = 0.032), LDL
(R = 0.272; p = 0.037), and triglycerides (R = 0.268;
p = 0.04). We found no similar associations with either
total or gynoid fat. Interestingly, despite similar ACTH
levels in both groups, MONW had significantly higher
cortisol levels both at baseline and in the dexamethasone
suppression test. However, in all the subjects levels of
ACTH, morning cortisol, and cortisol after dexamethasone
were within the reference values. In logistic regression
analysis, cortisol (OR 1.34; 95 % CI 1.08–1.67; p \ 0.01)
and %BF (OR 1.14; 95 % CI 1.05–1.23; p \ 0.01), after
adjusting for confounders, were independent predictors of
the MONW phenotype.
The distribution of the glucocorticoid receptor poly-
morphisms BCL1 and N363S was similar in MONW and
controls (Table 2). All studied genotypes followed the
Hardy–Weinberg equilibrium in both cases and controls.
Women with the BCL1 polymorphism (GC and GG
genotypes) had lower BMI than CC carriers [21.60 kg/m2
(range 20.17–23.42) versus 22.71 kg/m2 (range
21.39–24.13); p = 0.023]. There were no other significant
differences in the studied parameters between women with
and without the BCL1 and N363S polymorphisms of the
glucocorticoid receptor gene. There were also no signifi-
cant differences in psychological features between MONW
and controls (Table 3). The total emotion control index was
positively correlated only with insulin and HOMA-IR and
additionally in MONW with glucose (Table 4). However,
no correlations were found between the total emotion
control index and cortisol. In the entire group of studied
women, there was fair to moderate agreement among three
of five personality traits (neuroticism, extroversion, and
openness to experience) and the total emotion control index
and its components (Table 5).
Discussion
We found that MONW women had significantly higher
BMI, %BF, android fat, and android/BF ratios but lower
gynoid/BF ratios than healthy controls. Moreover, %BF
was an independent predictor of the MONW phenotype.
Table 2 The distribution of glucocorticoid receptor polymorphisms
BCL1 and N363S
Genotype MONW (n) (%) Controls (n) (%) p value
N363S
AA 54 (100) 60 (93.8)
AG 0 4 (6.2) 0.124
GG 0 0
BCL1
CC 22 (40.7) 23 (35.9)
GC 28 (51.9) 32 (50.0) 0.502
GG 4 (7.4) 9 (14.1)






























Neuroticism 5.0 (3–7) 4.82 (2–7) 0.733
Extroversion 6.02 (4–8) 6.01 (5–7) 0.976
Openness 5.72 (5–7) 5.92 (5–7) 0.472
Agreeableness 5.34 (4–7) 5.57 (4–7) 0.732
Conscientiousness 6.29 (5–8) 6.32 (5–7) 0.838
CECS, Courtauld Emotional Control Scale; NEO-FFI, NEO-Five
Factor Inventory; IQR, Interquartile range
Table 4 Correlations between total emotion control index and bio-
chemical parameters in MONW and controls
MONW Controls
R p value R p value
Glucose (mmol/l) 0.28 0.029 0.14 0.234
Insulin (lIU/ml) 0.71 <0.001 0.29 0.012
HOMA-IR 0.71 <0.001 0.32 0.006
Cortisol (nmol/l) 0.04 0.772 0.10 0.417
Cortisol after dexamethasone
(nmol/l)
0.16 0.479 -0.30 0.220
ACTH (pmol/l) 0.03 0.875 -0.03 0.881
Copeptin (pmol/l) -0.34 0.067 -0.22 0.361
Spearman rank correlation coefficients
Bold values are statistically significant (p \ 0.05)
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These findings strongly support the results of previous
studies that MONW is closely associated with increased
total adiposity as well as unfavorable fat distribution.
Studies evaluating hypothalamic–pituitary–adrenal axis
activity in obesity have yielded inconsistent results. Some
earlier reports demonstrated a causal relationship between
hypothalamic–pituitary–adrenal axis upregulation and
obesity or metabolic syndrome [14, 15, 25, 26]. In pre-
menopausal obese women, Marin et al. [25] demonstrated
that 24-h urine cortisol excretion correlated significantly
with abdominal obesity. Similarly, cortisol responses to
ACTH and CRH were higher in obese women with
abdominal obesity than in women with peripheral fat dis-
tribution [26]. Other studies demonstrated a significant
relationship between morning plasma cortisol and compo-
nents of the metabolic syndrome [27]. In our study,
MONW showed significantly higher morning cortisol
concentration as well as higher cortisol in the dexametha-
sone suppression test. We also noted that morning and
postdexamethasone cortisol levels positively correlated
with total cholesterol and triglycerides. Moreover, cortisol
levels after dexamethasone also correlated with LDL. In
logistic regression, cortisol concentration was an indepen-
dent risk factor for the MONW phenotype. To our
knowledge, this is the first report demonstrating such
associations in MONW. Our results may suggest hypo-
thalamic–pituitary–adrenal axis hyperactivity in MONW,
closely associated with unfavorable lipid profiles. Thus, it
seems that cortisol might be involved in the development
of some metabolic disorders, even when its plasma con-
centrations remain within normal range. On the other hand,
recent studies have failed to demonstrate any associations
between cortisol level and obesity or metabolic syndrome
[28], suggesting that cortisol dysregulation may occur only
in various subpopulations (which still need to be identified)
of obese and/or insulin-resistant subjects. In addition, it has
been demonstrated that local and systematic glucocorticoid
action may be amplified by the expression of glucocorti-
coid receptor polymorphisms. In the general population,
the BCL1 polymorphism was associated with higher glu-
cocorticoid sensitivity [29, 30]; while the N363S poly-
morphism influenced the risk of coronary heart disease and
was associated with higher BMI and unfavorable lipid
profiles, although reports were not consistent [31–33].
There have been no earlier reports investigating the pre-
sence of glucocorticoid receptor polymorphisms in
MONW. Aside from significantly lower BMI in BCL1
carriers, we did not find any associations among the pre-
sence of the BCL1 or N363S polymorphisms, cortisol
level, and metabolic disorders. Moreover, the frequency of
both polymorphisms investigated in our study seems to
exclude their association with MONW. We found that the
N363S polymorphism was present only in 6.25 % of con-
trols, while in MONW it was not observed at all. On the
other hand, the incidence of the BCL1 polymorphism was
significantly higher than the incidence of MONW. There-
fore, it seems neither of the studied polymorphisms are
associated with the MONW phenotype.
In addition to direct relationships among cortisol,
obesity, and metabolic syndrome, evidence also suggests
that perceived psychological stress and personality traits
may contribute to the risk of cardiovascular disease and
metabolic disorders [34, 35]. In the present study, we
addressed this issue in our healthy, normal-weight popu-
lation by assessing basic personality traits and ability to
suppress negative emotions. Overall, there were no dif-
ferences in the tested psychological parameters between
MONW and controls; although some correlations relating
to metabolic disorders were found. The total emotion
control index positively correlated with fasting glucose,
insulin, and HOMA-IR. The tendency to suppress negative
emotions in CECS also correlated with some personal
traits: positively with neuroticism and inversely with
openness and extraversion. These results may indicate that
some psychological features may predispose individuals to
develop metabolic abnormalities, namely insulin resis-
tance. The multilateral connections between assessed
parameters may suggest a constellation of psychological
characteristics that substantially contributes to the risk for
the MONW phenotype. The influence of psychological
traits on stress adaptive mechanisms, hypothalamic–pitui-
tary–adrenal axis activity, and cortisol levels may mediate
this kind of reaction. In turn, this, along with the study of
Abraham et al. [27], may suggest that specific trait
Table 5 Correlations between
emotion control and personality




Bold values are statistically
significant (p \ 0.05)
Total emotion control
index
Anger control Anxiety control Depression
control
R p R p R p R p
Neuroticism 0.20 0.023 0.22 0.020 0.11 0.268 0.49 <0.001
Extroversion -0.28 0.002 -0.33 <0.001 -0.22 0.020 -0.37 <0.001
Openness to experience -0.25 0.005 -0.067 0.483 -0.25 <0.001 -0.20 0.032
Conscientiousness 0.03 0.766 -0.05 0.634 0.15 0.116 -0.16 0.490
Agreeableness -0.01 0.898 0.18 0.060 -0.26 0.006 -0.07 0.101
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questionnaires may be more useful than general stress
questionnaires in understanding the role of stress in meta-
bolic abnormalities typically found in MONW. However,
this suggestion needs further study, as no role for psy-
chological factors in pathogenesis of MONW has been
elucidated as yet.
We could not demonstrate any significant associations
among copeptin levels and metabolic parameters, anthro-
pometric measurements, body composition, or MONW
occurrence. Previous reports found positive correlations
between plasma copeptin concentrations and the preva-
lence of type 2 diabetes, insulin resistance, and metabolic
syndrome [19, 20]. However, these studies were performed
on populations that significantly differed from our sample
in size, ethnicity, age, weight, and adiposity. In these
studies, plasma copeptin levels significantly correlated with
BMI, fasting plasma glucose and insulin, HOMA-IR, tri-
glycerides, and HDL [19]. We were unable to confirm
these results, likely due to younger subjects, lower BMI,
and a relatively modest sample size.
When interpreting our data, it is appropriate to consider
certain limitations of our study. The main limitation is its
cross-sectional design. Hence, the associations presented
between independent factors and outcome variables do not
necessarily represent causal relationships. We studied a
relatively large sample of healthy, premenopausal Polish
women with narrow BMI, BF, and age ranges. Therefore,
the data presented in this study may not be applicable to
general populations or other ethnicities. Second, in addition
to possible inter-operator variation, there is an intra-
equipment variation in DXA measurements even within
equipment supplied by the same manufacturer; which may
influence the reliability of measurements in population-
based studies. Moreover, in some cases, an automatic scan
mode does not fix the markers accurately within the studied
region of interest, which requires manual corrections. To
minimize such technical errors, we used the same DXA
scanner and software version for the entire study duration.
Additionally, all scans were analyzed by the same techni-
cian. Third, our study evaluated systemic cortisol levels
and did not evaluate the role of cortisol within tissues or
cortisol production rates. It has been suggested that minor
changes in hypothalamic–pituitary–adrenal axis activity,
inflammatory status, and psychological factors may con-
tribute jointly to the pathogenesis of obesity and metabolic
syndrome [30], and hence, also possibly to the MONW
phenotype. Fourth, albeit Neo-FFI, in general, provides a
quick, reliable, and accurate measure of the five domains of
personality and CECS is a valuable psychometric instru-
ment in the assessment of perceptions of psychological
stressors; it is unclear whether these tools are also sensitive
enough to assess which personality traits are MONW-
specific, or how personality is related with the individual
perceptions to metabolic stressors. Therefore, further
studies are needed to elucidate these relationships. Finally,
one of the diagnostic criteria used in this study was based
on arbitrary assumed cut values for HOMA-IR, which
represents only a surrogate method for the assessment of
insulin resistance, derived from a single measurement of
fasting glucose and insulin. Although the same criterion
was used in earlier reports [3, 35], our study emphasizes
the urgent need to develop more adequate diagnostic cri-
teria which could be widely applied to the early identifi-
cation of normal-weight subjects at risk for metabolic
abnormalities.
In conclusion, we found that the MONW phenotype was
associated not only with hypothalamic–pituitary–adrenal
axis dysregulation, unfavorable metabolic profiles, and fat
accumulation but also with normal personality traits, co-
peptin levels, and distribution of the BCL1 and N363S
glucocorticoid receptor gene polymorphisms.
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